Where naturopathic tradition meets clinical evidence.
Research-grade breakdowns of peptide science, bioregulators, mitochondrial biology, and metabolic interventions. Every claim traced back to the primary literature — no marketing copy.
The Australian Peptide Research Landscape 2026
A comprehensive reference mapping Australian peptide research in 2026: TGA regulatory framework, major peptide classes, research institutions, compounding rules, and 2024–26 policy shifts.
Epithalon and Telomere Biology: Khavinson's Research
A practitioner-focused review of epithalon telomere research: the mechanisms proposed by Vladimir Khavinson, what the published animal and human studies actually demonstrate, and how integrative clinicians contextualise this pineal-derived tetrapeptide.
CJC-1295 and Ipamorelin: GHRH and Ghrelin Receptor Synergy
CJC-1295 and Ipamorelin act on different receptor classes — GHRH-R and the ghrelin receptor — to amplify the natural pulsatile growth hormone pulse. This article covers how the two mechanisms complement each other and why the combination produces cleaner GH release than either compound alone.
Research Peptides: The Complete Guide to Mechanisms
A comprehensive reference covering all major categories of research peptides: tissue repair, cognitive enhancement, metabolic regulation, longevity, and mitochondrial function. Covers mechanisms, evidence quality, regulatory status, and cross-category comparisons.
Five research lanes. One editorial standard.
Therapeutic peptide mechanisms, dosing science, and clinical trial evidence.
17 articlesGLP-1 biology, insulin signalling, and metabolic adaptation research.
10 articlesShort peptide bioregulators including Selank, Semax, and Epitalon.
8 articlesMitochondria-targeted peptides, NAD+ biology, and cellular energy.
9 articlesLongevity research, epigenetic clocks, and telomere science.
Science without the marketing layer.
Every article is built from primary literature — clinical trials, meta-analyses, and peer-reviewed research. We translate the mechanism, not the marketing copy. When evidence is preliminary, conflicting, or absent, we say so explicitly.